MaxCyte, Inc. $MXCT Shares Purchased by Renaissance Technologies LLC

Renaissance Technologies LLC boosted its holdings in shares of MaxCyte, Inc. (NASDAQ:MXCT) by 153.3% during the 1st quarter, HoldingsChannel reports. The firm owned 1,993,200 shares of the company’s stock after purchasing an additional 1,206,300 shares during the period. Renaissance Technologies LLC’s holdings in MaxCyte were worth $1,400,000 as of its most recent filing with the SEC.

Other institutional investors also recently bought and sold shares of the company. Capricorn Fund Managers Ltd purchased a new stake in shares of MaxCyte in the first quarter valued at about $5,760,000. Brooklands Fund Management Ltd acquired a new position in MaxCyte in the 1st quarter valued at about $1,538,000. Kennedy Capital Management LLC acquired a new position in MaxCyte in the 3rd quarter valued at about $3,330,000. AXA S.A. raised its stake in MaxCyte by 123.2% during the 2nd quarter. AXA S.A. now owns 2,202,378 shares of the company’s stock valued at $4,801,000 after acquiring an additional 1,215,481 shares during the last quarter. Finally, Millennium Management LLC lifted its position in MaxCyte by 1,082.6% during the 4th quarter. Millennium Management LLC now owns 1,292,773 shares of the company’s stock worth $2,004,000 after acquiring an additional 1,183,461 shares during the period. 68.81% of the stock is currently owned by institutional investors and hedge funds.

MaxCyte Stock Up 2.4%

NASDAQ MXCT opened at $1.27 on Thursday. The stock has a market capitalization of $136.04 million, a P/E ratio of -3.43 and a beta of 1.48. MaxCyte, Inc. has a 52-week low of $0.64 and a 52-week high of $1.86. The firm has a 50-day moving average price of $1.19 and a 200 day moving average price of $0.98.

MaxCyte (NASDAQ:MXCT) last issued its earnings results on Wednesday, August 12th. The company reported ($0.08) earnings per share for the quarter, topping the consensus estimate of ($0.09) by $0.01. MaxCyte had a negative net margin of 121.16% and a negative return on equity of 20.03%. The company had revenue of $6.50 million for the quarter, compared to analyst estimates of $6.51 million. On average, equities research analysts expect that MaxCyte, Inc. will post -0.29 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

MXCT has been the topic of several analyst reports. Wall Street Zen upgraded MaxCyte from a “sell” rating to a “hold” rating in a research note on Saturday, May 16th. Weiss Ratings upgraded MaxCyte from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, July 28th. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, MaxCyte presently has an average rating of “Hold” and a consensus price target of $5.00.

About MaxCyte

MaxCyte, Inc (NASDAQ: MXCT) is a clinical?stage cell therapy platform company that develops and commercializes proprietary flow electroporation technology for the delivery of macromolecules into living cells. The company’s instruments and consumables are designed to support research, preclinical development and clinical?scale manufacturing of cell therapies across a variety of modalities, including engineered T cells, natural killer (NK) cells and induced pluripotent stem cell (iPSC) therapies.